Type 2 & other diabetes

Cardiovascular effectiveness and safety of SGLT2 inhibitors vs DPP4 inhibitors by dementia status: a cohort study of older adults with diabetes

DiabetologiaPublished Population-based cohort study

Authors' conclusion

While SGLT2i might provide cardiorenal protection among those with dementia, closer monitoring may be warranted due to greater susceptibility to diabetic ketoacidosis.

Study context

Population
Community-dwelling adults aged ≥66 years with diabetes initiating SGLT2i or DPP4i (2016–2022), Ontario, Canada; stratified by dementia status2,481 pairs with dementia
Exposure
SGLT2i vs DPP4i initiation, by dementia status
Outcome
Composite of:
  • All-cause mortality or hospitalisation for ischaemic stroke
  • MI
  • HF
Methodological detailstarget trial emulation, propensity-score matched 1:1, stratified by dementia status, linkable administrative datasets
  • Target trial emulation
  • Propensity-score matched 1:1
  • Stratified by dementia status
  • Linkable administrative datasets

Main finding

As reported in the abstract

Composite effectiveness endpoint, by dementia status

IRD per 1000 person-years

−61.1

95% CI −78.2 to −43.9

Dementia; NNT: 20

IRD per 1000 person-years

−21.7

95% CI −23.7 to −19.7; homogeneity: p<0.001

No dementia; NNT: 43

Observational data: associations, not effects.

Further findings

OutcomeIRD per 1000 person-years (95% CI)
All-cause mortality, dementiaNNT: 25−51.2 (−65.7 to −36.7)
Hospitalisation for HF, dementiaNNT: 99−16.4 (−24.6 to −8.2)

Safety

OutcomeIRD per 1000 person-years (95% CI)
Acute kidney injury, dementiaNNT: 76−39.7 (−55.0 to −24.4)
Genital infection, dementiaNNH: 649.7 (3.7–15.6)

DKA, dementia vs no dementia

Absolute increase in DKA with SGLT2i greater among those with dementia vs no dementia
homogeneity: p=0.015

Original publication

Cardiovascular effectiveness and safety of SGLT2 inhibitors vs DPP4 inhibitors by dementia status: a cohort study of older adults with diabetes. Diabetologia. Published 8 November 2025. doi:10.1007/s00125-025-06595-0

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.